Form 8-K · Current report
Johnson & Johnson 8-K, filed Jul 29, 2026
- Filed
- CIK
- 0000200406
- Accession no.
- 0000200406-26-000163
Summary
Johnson & Johnson completed its $1 billion cash acquisition of Firefly Bio, Inc., whose Firelink degrader antibody conjugate platform targets pan-KRAS and other drivers of hard-to-treat solid tumors, and entered strategic agreements and a collaboration with Sail Biomedicines. The company said the two transactions will reduce 2026 adjusted EPS by roughly $0.64 and 2027 adjusted EPS by roughly $1.36, and it lowered its full-year 2026 guidance accordingly.
Key points
- Johnson & Johnson said the combination of the Firefly acquisition and the Sail transaction will reduce 2026 adjusted operational EPS and adjusted EPS by about $0.64, and 2027 figures by about $1.36, assuming Sail hits certain development milestones and J&J exercises its option.
- J&J lowered its full-year 2026 adjusted operational EPS guidance to $10.86–$11.01 from $11.50–$11.65, and adjusted EPS to $10.96–$11.11 from $11.60–$11.75.
- The Firefly transaction will be accounted for as an asset acquisition, producing an in-process research and development charge of approximately $1 billion in the third quarter of 2026.
- John Reed, J&J's executive vice president of Innovative Medicine R&D, said bringing Firefly Bio's technology together with the company's oncology and antibody engineering expertise should accelerate development of more precise therapies.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 7.01 Regulation FD Disclosure On July 29, 2026, Johnson & Johnson (the “Company”) announced the completion of the acquisition of Firefly Bio, Inc. (“Firefly”) and the entry into strategic agreements and collaboration with Sail Biomedicines (“Sail”). The combination of these two transactions is expected to reduce the Company’s adjusted operational earnings per share (Adjusted Operational EPS) and adjusted earnings per share (Adjusted EPS) by approximately $0.64 in 2026, consisting of approximately $0.46 attributable to the Firefly acquisition and approximately $0.18 attributable to the Sail transaction. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.